It has no cure and so far treatments have focused more on managing symptomsAlzheimer's disease is the most common form of dementia and is a physical brain condition that causes impaired memory, thinking and behaviour.
Full results — published in the New England Journal of Medicine [NEJM] — showed lecanemab modestly slowed the progression of Alzheimer's over an 18-month trial period. Scientia Professor Henry Brodaty is co-director of the Centre for Healthy Brain Ageing at the University of New South Wales . "This is the first trial to reach its primary outcome as stipulated, in reducing the rate of cognitive decline. So, it's quite exciting.Professor Brodaty said trial participants declined by about half a point less than the people not on the drug.
"I'm an optimist," he said. "This is the first of the new generation of Alzheimer's drugs that has actually shown improvements in cognition, a slowing of decline — not a huge impact — but the first drug to actually show that.
ABCscience eat meat, its that simple (why do we pay ABC $1.1Billion?)
It's early stages and I hear this drug has many bad side effects…
. Ramping up the immune system to attack amyloid in the brain, can increase the risk of systemic inflammation and haemorrhagic stroke, and cause brain swelling and bleeding. . Brain health requires monitoring serum levels of toxic and beneficial gut microbiota metabolites. .